Mednet Logo
SpecialtiesHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How would you approach a Follicular grade 1-2 NHL found on a terminal ileum biopsy with otherwise negative EGD and colonoscopy and contrast enhanced CT scan?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Dana-Farber Cancer Institute

At our facility, we have treated a significant number of patients with low grade lymphoma isolated to a single fixed site within the GI tract with excellent long term results. It is worth considering a dose of 2400 rads to the involved site.

What is your threshold for transfusing platelets in an asymptomatic patient after autologous stem cell transplant?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Pittsburgh Medical Center

My thresold for transfusing platelets in an asymptomatic patient after autologous stem cell transplant is the same as with other patients - transfuse for plts<10 unless febrile or if any bleeding complications, at which time the threshold would be higher.

Do you have any concerns about enhanced radiation toxicity with any of the novel agents used to treat multiple myeloma?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Washington University School of Medicine

I agree with Dr Vesole.

How do you approach CNS prophylaxis in double-hit lymphoma patients?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Maryland Cancer Center

There is no consensus about the need for IT chemo for CNS prophylaxis in DLBCL. Factors such as IPI, the number and location of extranodal sites of disease, and LDH may be used to identify a group of patients with aggressive NHL who are at particularly high risk for CNS recurrence and might therefor...

How do you manage patients with primary refractory Hodgkin lymphoma?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Without advising directly on this particular case, which is difficult to do without more information, a few principles in lymphoma management may be helpful: 1. Whenever there is discordance in the clinical picture, or whenever initial management would be drastically changed, it is always prudent to...

When do you combine hypomethylating agents with venetoclax or gemtuzumab ozogamicin in elderly patients with AML who are ineligible for intensive chemotherapy?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Columbia University Medical Center

In September, 2017, the FDA granted approval for gemtuzumab ozogamicin (GO) in combination with daunorubicin and cytarabine (DA) and as a monotherapy for the treatment of adult patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML). Approval of GO monotherapy was based on a randomi...

Would you consider using daratumumab in the first line setting for non-transplant eligible multiple myeloma?

2
5 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Michigan

Agree as above; you cannot fairly compare PFS when the treatment arms have different durations of therapy.One could argue that the current standard for previously untreated elderly myeloma patients is continuous lenalidomide and dexamethasone, as described in the FIRST study, (Benboubker et al, NEJM...

How are you making the diagnosis of chronic lymphocytic leukemia transforming to prolymphocytic leukemia?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Stanford University

Looking at the trend of pro-lymphocyte increase will help in addition to clinical signs of progressive disease (splenomegaly). It is useful to check for TP53 and MYC translocations since these are common in PLL. As you mentioned, >55% pro-lymphocytes has been used to diagnosed PLL based on a report ...

Do you think there will be a role for duvelisib in the treatment of relapsed/refractory chronic lymphocytic leukemia?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · UPMC Hillman Cancer Center

I believe this agent could find a home for therapy in CLL as it is given by itself provided that further efficacy is demonstrated in a population where it would be most likely used, ibrutinib resistant CLL. Additionally, incorporation into non-BTK inhibitor combinations would also be possible. Given...

Would you consolidate marginal zone lymphoma transformed to a high grade B-cell lymphoma with a stem cell transplant?

4
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of British Columbia Faculty of Medicine

The transformed lymphoma that develops out of indolent small B cell lymphoma such as marginal zone lymphoma, follicular lymphoma or lymphoplasmacytic lymphoma, is typically diffuse large B cell lymphoma (DLBCL). When this type of transformed DLBCL develops in a patient who has not previously receive...